ORX489
/ Centessa
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 18, 2026
A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years
(clinicaltrials.gov)
- P1 | N=212 | Recruiting | Sponsor: Centessa Pharmaceuticals (UK) Limited
New P1 trial
March 24, 2025
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
(GlobeNewswire)
- "Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025: ORX489 in IND-enabling studies for the treatment of neuropsychiatric disorders."
Preclinical • Psychiatry
1 to 2
Of
2
Go to page
1